Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Background Limited evidence suggests that multifactorial interventions for control of glucose, blood pressure, and lipids reduce macrovascular complications and mortality in patients with type 2 diabetes. However, safe and effective treatment targets for these risk factors have not been determined for such interventions.Methods In this multicentre, open-label, randomised, parallel-group trial, undertaken at 81 clinical sites in Japan, we randomly assigned (1:1) patients with type 2 diabetes aged 45-69 years with hypertension, dyslipidaemia, or both, and an HbA 1c of 6·9% (52·0 mmol/mol) or higher, to receive conventional therapy for glucose, blood pressure, and lipid control (targets: HbA 1c <6·9% [52·0 mmol/mol], blood pressure <130/80 mm Hg, LDL cholesterol <120 mg/dL [or 100 mg/dL in patients with a history of coronary artery disease]) or intensive therapy (HbA 1c <6·2% [44·3 mmol/mol], blood pressure <120/75 mm Hg, LDL cholesterol <80 mg/dL [or 70 mg/dL in patients with a history of coronary artery disease]). Randomisation was done using a computer-generated, dynamic balancing method, stratified by sex, age, HbA 1c, and history of cardiovascular disease. Neither patients nor investigators were masked to group assignment. The primary outcome was occurrence of any of a composite of myocardial infarction, stroke, revascularisation (coronary artery bypass surgery, percutaneous transluminal coronary angioplasty, carotid endarterectomy, percutaneous transluminal cerebral angioplasty, and carotid artery stenting), and all-cause mortality. The primary analysis was done in the intention-to-treat population. This study is registered with ClinicalTrials.gov, number NCT00300976.Findings Between June 16, 2006, and March 31, 2009, 2542 eligible patients were randomly assigned to intensive therapy or conventional therapy (1271 in each group) and followed up for a median of 8·5 years (IQR 7·3-9·0). Two patients in the intensive therapy group were found to be ineligible after randomisation and were excluded from the analyses. During the intervention period, mean HbA 1c, systolic blood pressure, diastolic blood pressure, and LDL cholesterol concentrations were significantly lower in the intensive therapy group than in the conventional therapy group (6·8% [51·0 mmol/mol] vs 7·2% [55·2 mmol/mol]; 123 mm Hg vs 129 mm Hg; 71 mm Hg vs 74 mm Hg; and 85 mg/dL vs 104 mg/dL, respectively; all p<0·0001). The primary outcome occurred in 109 patients in the intensive therapy group and in 133 patients in the conventional therapy group (hazard ratio [HR] 0·81, 95% CI 0·63-1·04; p=0·094). In a post-hoc breakdown of the composite outcome, frequencies of all-cause mortality (HR 1·01, 95% CI 0·68-1·51; p=0·95) and coronary events (myocardial infarction, coronary artery bypass surgery, and percutaneous transluminal coronary angioplasty; HR 0·86, 0·58-1·27; p=0·44) did not differ between groups, but cerebrovascular events (stroke, carotid endarterectomy, percutaneous transluminal cerebral angioplasty, and carotid artery stenting) were significantly less frequent in the intensive therapy group (HR 0·42, 0·24-0·74; p=0·002). Apart from non-severe hypoglycaemia (521 [41%] patients in the intensive therapy group vs 283 [22%] in the conventional therapy group, p<0·0001) and oedema (193 [15%] vs 129 [10%], p=0·0001), the frequencies of major adverse events did not differ between groups.Interpretation Our results do not fully support the efficacy of further intensified multifactorial intervention compared with current standard care for the prevention of a composite of coronary events, cerebrovascular events, and all-cause mortality. Nevertheless, our findings suggest a potential benefit of an intensified intervention for the prevention of cerebrovascular events in patients with type 2 diabetes.Funding Ministry of Health, Labour and Welfare of Japan, Asahi Kasei Pharma, Astellas Pharma, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly, GlaxoSmithKline, Kissei Pharmaceutical, Kowa Pharmaceutical, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, MSD, Novartis Pharma, Novo Nordisk, Ono Pharmaceutical, Pfizer, Sanwa Kagaku Kenkyusho, Shionogi, Sumitomo Dainippon Pharma, Taisho Toyama Pharmaceutical, and Takeda.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Key problems in optimally treating patients with T2DM and CVD are the low rate of detection of T2DM in patients with CVD, the low referral rate to diabetes specialists, and the difficulty of prolonged adherence to medication or lifestyle interventions in this patient group.”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [367]
In the citing paper
“Of patients with known diabetes, 31% had been advised to attend a diabetes clinic, though only 24% attended.”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [367]
In the citing paper
“Only 58% of dysglycaemic patients were prescribed all cardio-protective drugs, and use of SGLT2 inhibitors or GLP-1 RAs was limited (3% and 1%, respectively).367”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [367]
In the citing paper
“The EUROASPIRE V survey reported that many patients with CVD (29.7%) had known diabetes, while 41.1% of those with unknown T2DM were dysglycaemic.367”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [367]
In the citing paper
“To date, no correlation has been shown between dietary carbohydrate intake and risk of diabetes or diabetic control status 13 , 14 .”
From Japanese clinical practice guideline for diabetes 2019 (2020) · cites this paper as [14]
12 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
James, P. A., Oparil, S., Carter, B. L., Cushman, W. C., Dennison-Himmelfarb, C., Handler, J., Lackland, D. T., LeFevre, M. L., MacKenzie, T. D., Ogedegbe, O., et al. (2014) · JAMA · doi:10.1001/jama.2013.284427 · Cited by 7,950
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378
Standards of medical care in diabetes—2013
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s011 · Cited by 4,369
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755
Cited by
Collet, J.-P., Thiele, H., Barbato, E., Barthélémy, O., Bauersachs, J., Bhatt, D. L., Dendale, P., Dorobantu, M., Edvardsen, T., Folliguet, T., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa575 · Cited by 5,037
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019)
Umemura, S., Arima, H., Arima, S., Asayama, K., Dohi, Y., Hirooka, Y., Horio, T., Hoshide, S., Ikeda, S., Ishimitsu, T., et al. (2019) · Hypertension Research · doi:10.1038/s41440-019-0284-9 · Cited by 1,880
Self-citation2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642
KDIGO 2020 Clinical practice guideline for diabetes management in chronic kidney disease
de Boer, I. H., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2020) · Kidney International · doi:10.1016/j.kint.2020.06.019 · Cited by 1,399
Metadata
- Authors
- Ueki, K., Sasako, T., Okazaki, Y., Kato, M., Okahata, S., Katsuyama, H., Haraguchi, M., Morita, A., Ohashi, K., Hara, K., Morise, A., Izumi, K., Ishizuka, N., Ohashi, Y., Noda, M., Kadowaki, T., Haneda, M., Iwashima, Y., Suda, T., Tamasawa, N., Daimon, M., Satoh, J., Takebe, N., Ishigaki, Y., Watanabe, T., Satoh, H., Kasai, K., Aso, Y., Ishibashi, S., Katayama, S., Ishikawa, S.-E., Kakei, M., Namai, K., Hashimoto, N., Suzuki, Y., Onishi, S., Yokote, K., Matsuda, M., Masuzawa, M., Hayashi, Y., Saito, S., Ogihara, N., Ishihara, H., Tajima, N., Utsunomiya, K., Shimada, A., Itoh, H., Kawamori, R., Watada, H., Hayashi, M., Mori, Y., Shiba, T., Isogawa, A., Sakura, H., Odawara, M., Tobe, K., Tsukamoto, K., Yamauchi, T., Teramoto, T., Hirata, Y., Uchimura, I., Ogawa, Y., Yoshino, G., Hirose, T., Kajio, H., Atsumi, Y., Shimada, A., Oikawa, Y., Araki, A., Ueki, A., Ohno, A., Kitaoka, M., Fujita, Y., Moriya, T., Tojo, T., Shichiri, M., Suzuki, D., Toyoda, M., Hamano, K., Komi, R., Terauchi, Y., Kuzuya, N., Yamada, M., Takamura, T., Imura, M., Tanaka, H., Hayashi, M., Kato, Y., Itoh, M., Suzuki, A., Nakayama, M., Sano, T., Nakashima, E., Sumida, Y., Yano, Y., Tanaka, T., Murata, K., Kashiwagi, A., Maegawa, H., Kono, S., Inagaki, N., Kosugi, K., Yasuda, T., Yoshimasa, Y., Kishimoto, I., Sato, T., Hosoi, M., Yamasaki, T., Matsuhisa, M., Shimomura, I., Taniguchi, A., Kuroe, A., Kurose, T., Ohara, T., Sakaguchi, K., Namba, M., Kaku, K., Fujiwara, M., Shimizu, I., Ono, K., Ebisui, O., Tanizawa, Y., Okada, Y., Natori, S., Kodera, T., Sato, N., Ide, M., Yamada, K., Umeda, F., Natori, S., Eto, T., Mimura, K., Hiramatsu, S., Inoue, T., Takei, R., Ogo, A., Eguchi, K., Kawasaki, E., Koide, Y., Araki, E., Jinnouchi, H., Yamamoto, H., Motoyoshi, M., Hiyoshi, T., Tanaka, Y., Momoki, T., Sato, K., Yoneyama, A., Ito, K., Sobajima, H., Ikegami, H., Ikeda, M., Ikeda, H., Takahashi, K., Makino, H., Ueda, Y., & Nakazato, M.
- Affiliations
- National Center for Global Health and Medicine (JP)
- The University of Tokyo (JP)
- Toranomon Hospital (JP)
- Toho University Ohashi Medical Center (JP)
- National Cancer Center Hospital (JP)
- Jichi Medical University (JP)
- Tokyo Takanawa Hospital (JP)
- The Cancer Institute Hospital (JP)
- Chuo University (JP)
- Saitama Medical University (JP)
- Corresponding author
- Kadowaki, Takashi
- ORCID
- Ueki, Kohjiro
- Sasako, Takayoshi
- Kato, Masayuki
- Okahata, Sumie
- Katsuyama, Hisayuki
- Hara, Kazuo
- Ishizuka, Naoki
- Ohashi, Yasuo
- Noda, Mitsuhiko
- Kadowaki, Takashi
- Haneda, Masakazu
- Daimon, Makoto
- Takebe, Noriko
- Ishigaki, Yasushi
- Watanabe, Tsuyoshi
- Satoh, Hiroaki
- Aso, Yoshimasa
- Ishibashi, Shun
- Katayama, Shigehiro
- Ishikawa, San-e
- Hashimoto, Naotake
- Yokote, Koutaro
- Matsuda, Masafumi
- Hayashi, Yoichi
- Ishihara, Hisamitsu
- Itoh, Hiroshi
- Kawamori, Ryuzo
- Watada, Hirotaka
- Hayashi, Michio
- Mori, Yasumichi
- Shiba, Teruo
- Isogawa, Akihiro
- Odawara, Masato
- Tobe, Kazuyuki
- Tsukamoto, Kazuhisa
- Yamauchi, Toshimasa
- Teramoto, Tamio
- Ogawa, Yoshihiro
- Hirose, Takahisa
- Kajio, Hiroshi
- Oikawa, Yoichi
- Araki, Atsushi
- Moriya, Tatsumi
- Tojo, Taiki
- Shichiri, Masayoshi
- Suzuki, Daisuke
- Toyoda, Masao
- Terauchi, Yasuo
- Takamura, Toshinari
- Tanaka, Hiroshi
- Hayashi, Masayuki
- Kato, Yasuhisa
- Suzuki, Atsushi
- Yano, Yutaka
- Tanaka, Tsuyoshi
- Murata, Kazuya
- Kashiwagi, Atsunori
- Maegawa, Hiroshi
- Inagaki, Nobuya
- Yasuda, Tetsuyuki
- Kishimoto, Ichiro
- Matsuhisa, Munehide
- Shimomura, Iichiro
- Kurose, Takeshi
- Sakaguchi, Kazuhiko
- Kaku, Kohei
- Tanizawa, Yukio
- Okada, Yosuke
- Sato, Naoichi
- Yamada, Kentaro
- Eto, Tomoaki
- Inoue, Tomoaki
- Kawasaki, Eiji
- Araki, Eiichi
- Jinnouchi, Hideaki
- Tanaka, Yasushi
- Sato, Koichiro
- Ito, Kenichi
- Ikegami, Hiroshi
- Ikeda, Masaki
- Ikeda, Hiroki
- Takahashi, Kenji
- Makino, Hirofumi
- Nakazato, Masamitsu
- Venue
- The Lancet Diabetes & Endocrinology
- Publisher
- Elsevier BV
- Published
- 2017-12
- Volume
- 5
- Issue
- 12
- Pages
- 951-964
- ISSN
- 2213-8587 (ISSN-L)
- OpenAlex
- W2767087620
- Cited by
- 313
- References
- 39
- Citations by year
- 2026: 18 · 2025: 25 · 2024: 38 · 2023: 41 · 2022: 31 · 2021: 45 · 2020: 47 · 2019: 42 · 2018: 24 · 2017: 1
- FWCI
- 24.62
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (am, 355 d)
- Locations
- The Lancet Diabetes & Endocrinology (acceptedVersion)
- PubMed (publishedVersion)
- Institutional Repositories DataBase (IRDB) (submittedVersion)
- Funders
- Kissei
- Bristol-Myers Squibb
- Boehringer Ingelheim Japan
- Eli Lilly and Company
- Daiichi-Sankyo
- Astellas Pharma US
- Ministry of Health, Labour and Welfare
- Japan Diabetes Foundation
- Novartis Pharma
- Ono Pharmaceutical
- Novartis
- Astellas Pharma
- Meso Scale Diagnostics
- Taisho Toyama Pharmaceutical Company
- Boehringer Ingelheim
- Mitsubishi Tanabe Pharma Corporation
- Takeda Pharmaceutical Company
- Kyowa Hakko Kirin
- Bayer
- Novo Nordisk
- AstraZeneca
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- type 2 diabetes, multifactorial intervention, tight glycemic control, HbA1c targets, blood pressure targets, LDL cholesterol targets, hypertension, dyslipidemia, cardiovascular events, myocardial infarction, stroke, revascularization, all-cause mortality, macrovascular complications, cardiovascular risk reduction, coronary artery disease, Japanese patients, middle-aged adults
- MeSH terms
- Aged, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Follow-Up Studies, Humans, Japan, Male, Middle Aged, Mortality, Causality, Treatment Outcome, Early Medical Intervention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial. https://app.cochat.ai/papers/10.1016/s2213-8587(17)30327-3
- The paper
- Ueki, K., Sasako, T., Okazaki, Y., Kato, M., Okahata, S., Katsuyama, H., Haraguchi, M., Morita, A., Ohashi, K., Hara, K., Morise, A., Izumi, K., Ishizuka, N., Ohashi, Y., Noda, M., Kadowaki, T., Haneda, M., Iwashima, Y., Suda, T., . . . Nakazato, M. (2017). Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(17)30327-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.